Annovis Bio, Inc. (ANVS) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Company: Annovis Bio, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Annovis is a late-stage clinical drug platform company focused on neurodegenerative diseases, specifically Alzheimer's disease (AD) and Parkinson's disease (PD). The company's lead product candidate is buntanetap, an orally administered small molecule designed to inhibit the synthesis of multiple neurotoxic proteins (APP, tau, alpha-synuclein, TDP43) to restore axonal transport and reduce neurodegeneration. The company has no commercial products and has never generated revenue.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(28,854) | $(24,590) |
| Operating Loss | $(29,695) | $(26,695) |
| Cash and Cash Equivalents (Year End) | $19,532 | $10,552 |
| Cash Used in Operating Activities | $(25,620) | $(21,895) |
| Cash Provided by Financing Activities | $34,600 | $26,692 |
| Accumulated Deficit | $(163,704) | $(134,849) |
| Current Liabilities | $3,635 | $3,881 |
Capital Structure: As of December 31, 2025, the company had 27,199,139 shares of common stock outstanding. The company raised approximately $34.6 million in net proceeds during 2025 through registered direct offerings, an underwritten public offering, and an At-The-Market (ATM) facility.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $4.3 million (17%) from 2024 to 2025, primarily driven by higher Research and Development (R&D) expenses.
- R&D Expenses: Increased by $5.2 million to $25.2 million. This was due to an $8.4 million increase in costs associated with the Phase 3 AD Trial and a $0.8 million increase in bioanalytical work, partially offset by decreases in clinical material manufacturing costs.
- G&A Expenses: Decreased by $2.2 million to $4.5 million, largely due to a $1.5 million reduction in stock-based compensation expense.
- Other Income: Total other income decreased by $1.3 million, primarily due to a reduction in the gain from the change in fair value of warrants ($0.1 million gain in 2025 vs. $3.6 million gain in 2024) and the absence of financing costs associated with the exhausted ELOC facility in 2025.
- Liquidity: Cash balances increased by $9.0 million year-over-year, bolstered by significant equity financing activities in 2025.
Guidance, Outlook, and Risks
Clinical Pipeline Status:
- Phase 3 AD Trial: Initiated in February 2025 with 760 patients. The 6-month symptomatic component is expected to read out in the second half of 2026; the 18-month disease-modifying component is expected to read out in the second half of 2027.
- PD Open-Label Extension (OLE): Initiated in January 2026 to evaluate long-term safety and efficacy in 500 patients.
- PDD Study: Protocol refinement is ongoing; initiation is contingent on additional funding.
Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for the twelve months following the issuance of the financial statements. The company does not have sufficient cash to fund operations for at least 12 months beyond the filing date and expects to fund operations only into the third quarter of 2026. The auditor's report includes an explanatory paragraph regarding this uncertainty.
Key Risks:
- Capital Requirements: The company requires substantial additional capital to complete clinical trials and commercialization. Failure to secure funding could force a reduction or termination of operations.
- Regulatory Approval: Success is heavily dependent on the approval of buntanetap. Clinical trials in AD and PD have historically high failure rates.
- Third-Party Dependence: Reliance on third-party CROs and CMOs for clinical trial conduct and manufacturing.
- Stock Listing: The company received a notice from the NYSE in March 2025 regarding non-compliance with listing standards (market cap and stockholders' equity) and has an 18-month plan to regain compliance.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next required financing round, as management projects funds only through Q3 2026.
- Phase 3 AD Trial Enrollment: Confirm patient enrollment rates and any potential delays in the pivotal 760-patient study.
- Financing Terms: Review the terms of recent equity offerings (October 2025 registered direct offerings and February 2025 ThinkEquity offering) for dilution impact and warrant exercise prices.
- NYSE Compliance: Monitor the company's progress in meeting the NYSE's continued listing standards (market capitalization and stockholders' equity) to avoid delisting.
- Patent Portfolio: Review the status of the 14 patent families, particularly the expiration dates (ranging from 2031 to 2045) and the coverage of the new "Form B" crystal structure.